Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04458363 · ClinicalTrials.gov registry record · Early Phase 1
Convalescent Plasma in Pediatric COVID-19
A Early Phase 1 study, sponsored by Emory University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 3
- Enrollment target
NCT04458363: Completed Early Phase 1 study, sponsored by Emory University.
NCT04458363 is a Early Phase 1 study that has completed, run by Emory University. The registered enrollment target is 3 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04458363, a Early Phase 1 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
COVID-19 is increasingly affecting children but convalescent plasma (CP) has not been adequately studied in children to date. The study will determine safety of convalescent plasma for pediatric patients with severe, or at high risk for severe, COVID-19 disease.
Primary Outcome
Safety of convalescent plasma for pediatric patients will be determined by capturing the grade 3-5 adverse events that are possible, probably or definitely related to the CP infusion, defined using the NCI Common Terminology Criteria for Adverse Events (CTCAE)
Interventions
- BIOLOGICAL Convalescent Plasma (CP)
- DRUG Standard COVID-19 therapies
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2020-07-04 |
| Est. Completion | 2020-09-01 |
| Phase | Early Phase 1 |
What the finished NCT04458363 record still lists
NCT04458363 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 2 interventions - of which Convalescent Plasma (CP) is the first listed.
NCT04458363 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04458363 about?
NCT04458363 is a clinical study titled "Convalescent Plasma in Pediatric COVID-19". COVID-19 is increasingly affecting children but convalescent plasma (CP) has not been adequately studied in children to date. The study will determine safety of convalescent plasma for pediatric patients with severe, or at high risk for severe, COVID-19 disease.
What is the current status of trial NCT04458363?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 3 participants. The study started on 2020-07-04. Estimated completion is 2020-09-01.
What interventions are being tested in trial NCT04458363?
The interventions under investigation include: Convalescent Plasma (CP) (BIOLOGICAL), Standard COVID-19 therapies (DRUG).
Who is sponsoring clinical trial NCT04458363?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04458363's enrollment target sits among peer trials
3 1949th of 2000 higher than 28 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI